Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway

Molecular Pharmacology

Volumn 82, Issue 6, 2012, Pages 1030-1041

  Yaseen, Alae ^a,c   Chen, Shuang ^a,c   Hock, Stefanie ^a,c   Rosato, Roberto ^a,c   Dent, Paul ^b   Dai, Yun ^a,c   Grant, Steven ^a,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLDEOXYURIDINE; CASPASE 8; CHLORIDE; DEATH RECEPTOR 5; FREE RADICAL; PANOBINOSTAT; REACTIVE OXYGEN METABOLITE; RESVERATROL; SHORT HAIRPIN RNA; SIRTUIN 1; TETRAKIS (4 BENZOIC ACID)PORPHYRIN CHLORIDE; UNCLASSIFIED DRUG; URIDINE DERIVATIVE; VORINOSTAT;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CELL PROTECTION; COMET ASSAY; DNA DAMAGE; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION;

ACETYLATION; APOPTOSIS; CASPASE 8; CELL LINE, TUMOR; DNA DAMAGE; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; LEUKEMIA, MYELOID, ACUTE; METALLOPORPHYRINS; MITOCHONDRIA; NF-KAPPA B; REACTIVE OXYGEN SPECIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; S PHASE; SIRTUIN 1; STILBENES; TRANSCRIPTION FACTOR RELA; U937 CELLS; UP-REGULATION;

EID: 84869859363     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.079624     Document Type: Article

References (56)

1. Athar M, Back JH, Kopelovich L, Bickers DR, and Kim AL (2009) Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys 486:95-102.
2. Baur JA and Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493-506. (Pubitemid 44136961)
3. Bernhard D, Tinhofer I, Tonko M, Hübl H, Ausserlechner MJ, Greil R, Kofler R, and Csordas A (2000) Resveratrol causes arrest in the S-phase prior to Fasindependent apoptosis in CEM-C7H2 acute leukemia cells. Cell Death Differ 7:834-842.
4. Bolden JE, Peart MJ, and Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784. (Pubitemid 44348499)
5. Chandra J (2009) Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies. Antioxid Redox Signal 11:1123-1137.
6. Chen CJ, Yu W, Fu YC, Wang X, Li JL, and Wang W (2009) Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway. Biochem Biophys Res Commun 378:389-393.
7. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, and Gan L (2005) SIRT1 protects against microglia-dependent amyloid-β toxicity through inhibiting NF-≲καππα∀B signaling. J Biol Chem 280:40364-40374. (Pubitemid 41779174)
8. Chen LF, Fischle W, Verdin E, and Greene WC (2001) Duration of nuclear NF-≲καππα∀B action regulated by reversible acetylation. Science 293:1653-1657. (Pubitemid 32807844)
9. Chen LF, Mu Y, and Greene WC (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF- ≲καππα∀B. EMBO J 21:6539-6548. (Pubitemid 35448431)
10. Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, Dent P, and Grant S (2008) Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 112:2439-2449.
11. Dai Y, Chen S, Wang L, Pei XY, Funk VL, Kramer LB, Dent P, and Grant S (2011a) Disruption of I≲καππα∀B kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors. J Biol Chem 286:34036-34050.
12. Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, and Grant S (2011b) Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-≲καππα∀B and Bim. Br J Haematol 153:222-235.
13. Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, Dent P, Jordan CT, and Grant S (2010) The NF (nuclear factor)- ≲καππα∀B inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol 151:70-83.
14. Dai Y, Rahmani M, Dent P, and Grant S (2005) Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF- ≲καππα∀B activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 25:5429-5444. (Pubitemid 40853579)
15. de la Lastra CA and Villegas I (2007) Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 35:1156-1160.
16. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, and Aggarwal BB (2003) Resveratrol blocks interleukin-1β-induced activation of the nuclear transcription factor NF- ≲καππα∀B, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 102:987-995. (Pubitemid 36917794)
17. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, et al. (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111:1060-1066. (Pubitemid 351213383)
18. Ge Y, Montano I, Rustici G, Freebern WJ, Haggerty CM, Cui W, Ponciano-Jackson D, Chandramouli GV, Gardner ER, Figg WD, et al. (2006) Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood 108:4126-4135. (Pubitemid 44913284)
19. Gianni D, Taulet N, Zhang H, DerMardirossian C, Kister J, Martinez L, Roush WR, Brown SJ, Bokoch GM, and Rosen H (2010) A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells. ACS Chem Biol 5:981-993.
20. Glozak MA, Sengupta N, Zhang X, and Seto E (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15-23. (Pubitemid 41691888)
21. Glozak MA and Seto E (2007) Histone deacetylases and cancer. Oncogene 26:5420-5432. (Pubitemid 47255924)
22. Grant S, Easley C, and Kirkpatrick P (2007) Vorinostat. Nat Rev Drug Discov 6:21-22. (Pubitemid 46020282)
23. Holmes-McNary M and Baldwin AS Jr (2000) Chemopreventive properties of transresveratrol are associated with inhibition of activation of the I≲καππα∀B kinase. Cancer Res 60:3477-3483. (Pubitemid 30482167)
24. Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, Brown K, Steward WP, and Gescher AJ (2011) Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases: safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 4:1419-1425.
25. Hussain AR, Uddin S, Bu R, Khan OS, Ahmed SO, Ahmed M, and Al-Kuraya KS (2011) Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines. PLoS One 6:e24703.
26. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, and Pelicci PG (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71-76. (Pubitemid 40215840)
27. Kim YM, Talanian RV, and Billiar TR (1997) Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 272:31138-31148. (Pubitemid 27527564)
28. Kramer MP and Wesierska-Gadek J (2009) Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose. Ann NY Acad Sci 1171:257-263.
29. Krämer OH, Knauer SK, Zimmermann D, Stauber RH, and Heinzel T (2008) Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 27:732-740. (Pubitemid 351186315)
30. Lee JH, Choy ML, Ngo L, Foster SS, and Marks PA (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107:14639-14644.
31. Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, Holyoake TL, Chen W, and Bhatia R (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21:266-281.
32. Liu T, Liu PY, and Marshall GM (2009) The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 69:1702-1705.
33. Low IC, Chen ZX, and Pervaiz S (2010) Bcl-2 modulates resveratrol-induced ROS production by regulating mitochondrial respiration in tumor cells. Antioxid Redox Signal 13:807-819.
34. Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, and Grant S (2004) The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64:2590-2600. (Pubitemid 38523917)
35. 2 and superoxide dismutase activity. Proc Natl Acad Sci USA 107:15123-15128.
36. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712-716. (Pubitemid 350207685)
37. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, et al. (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11:77-84. (Pubitemid 40215841)
38. Ogino K, Kodama N, Nakajima M, Yamada A, Nakamura H, Nagase H, Sadamitsu D, and Maekawa T (2001) Catalase catalyzes nitrotyrosine formation from sodium azide and hydrogen peroxide. Free Radic Res 35:735-747. (Pubitemid 34065663)
39. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, et al. (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285:8340-8351.
40. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, et al. (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148:421-433.
41. 1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood 118:5189-5200.
42. Petruccelli LA, Dupéré-Richer D, Pettersson F, Retrouvey H, Skoulikas S, and Miller WH Jr (2011) Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One 6:e20987.
43. Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, Raynaud S, and Auberger P (2010) Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 70:1042-1052.
44. Rosato RR, Almenara JA, Cartee L, Betts V, Chellappan SP, and Grant S (2002) The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol Cancer Ther 1:253-266.
45. Rosato RR, Almenara JA, Coe S, and Grant S (2007) The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 67:9490-9500. (Pubitemid 47535939)
46. Rosato RR, Almenara JA, and Grant S (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63:3637-3645. (Pubitemid 36793047)
47. Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, and Grant S (2010) Histone deacetylase inhibitors activate NF-≲καππα∀B in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem 285:10064-10077.
48. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, and Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98:10833-10838. (Pubitemid 32878706)
49. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, and Peter ME (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17:1675-1687. (Pubitemid 28119121)
50. Schilder YD, Heiss EH, Schachner D, Ziegler J, Reznicek G, Sorescu D, and Dirsch VM (2009) NADPH oxidases 1 and 4 mediate cellular senescence induced by resveratrol in human endothelial cells. Free Radic Biol Med 46:1598-1606.
51. Subramanian C, Opipari AW Jr, Bian X, Castle VP, and Kwok RP (2005) Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:4842-4847. (Pubitemid 40471541)
52. Tsan MF, White JE, Maheshwari JG, and Chikkappa G (2002) Anti-leukemia effect of resveratrol. Leuk Lymphoma 43:983-987. (Pubitemid 34460880)
53. Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, and Agarwal R (2005) Resveratrol causes Cdc2-Tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 26:1978-1987. (Pubitemid 41631273)
54. Xu WS, Parmigiani RB, and Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541-5552. (Pubitemid 47255934)
55. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, and Mayo MW (2004) Modulation of NF-≲καππα∀B-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369-2380. (Pubitemid 38954844)
56. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, and Yu Q (2005) Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 102:16090-16095. (Pubitemid 41552872)